Shared on30 Aug 25Fair value Increased 38%
Phibro Animal Health’s analyst price target has been raised to $32.50, reflecting increased confidence in above-consensus FY26 guidance, successful integration of recent acquisitions, and strengthened forward outlook, despite some concerns over the sustainability of growth. Analyst Commentary Strong initial FY26 guidance significantly above Street consensus, indicating improved profit outlook.
Shared on23 Apr 25Fair value Decreased 5.26%
AnalystConsensusTarget has decreased future PE multiple from 6.3x to 5.4x.
Shared on17 Apr 25Fair value Decreased 8.41%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 6.03%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Decreased 20%
AnalystConsensusTarget has decreased revenue growth from 16.1% to 12.4% and increased profit margin from 7.9% to 9.4%.